Eva Muñoz‐Couselo

5.8k citations
155 papers · 4.3k · 3 hit papers · h-index 35

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • Cutaneous Melanoma Detection and Management
    • Cancer Cells and Metastasis
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 71
    • Cutaneous Melanoma Detection and Management 21
    • Inflammatory Biomarkers in Disease Prognosis 4
    • Breast Cancer Treatment Studies 8
    • Cancer Genomics and Diagnostics 5

Eva Muñoz‐Couselo

142 papers receiving 4.2k citations

Eva Muñoz‐Couselo's Hit Papers

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial 2021 · 387 citations
3870+3+7Years since publication100200300400

Peers

Eva Muñoz‐Couselo
Comparison fields: 5 of 87
  • Oncology 2.1k
  • Cancer Research 620
  • Cell Biology 262
  • Molecular Biology 796
  • Immunology 157
Replace Stanley W. McCarthy with:
Stanley W. McCarthy Australia
Hiroyuki Katoh Japan
Hee Eun Lee South Korea
Raymond Couric Wadlow United States
Kai Fu United States
Jian‐Yong Shao China
Yun Gong United States
Karen Dresser United States
Lorena Losi Italy
Carlos Antonio Torres-Cabala United States
Eva Muñoz‐Couselo relative to Stanley W. McCarthy Australia Stanley W. McCarthy's profile →
Citations per field
00.5×5×12.2×
Stanley W. McCarthy · 1×
Citations per year

Countries citing papers authored by Eva Muñoz‐Couselo

Since Specialization
Citations

This map shows the geographic impact of Eva Muñoz‐Couselo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Muñoz‐Couselo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Muñoz‐Couselo more than expected).

Fields of papers citing papers by Eva Muñoz‐Couselo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Muñoz‐Couselo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Muñoz‐Couselo. The network helps show where Eva Muñoz‐Couselo may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Muñoz‐Couselo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Muñoz‐Couselo Line = papers co-authored together Eva Muñoz‐Couselo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Hit paper breakdown →
2015468
2
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2021387
3
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Hit paper breakdown →
2020327
4 2021155
5 2017135
6 2017132
7 2011130
8 2022126
9 2018112
10 2015103
11 201792
12 202184
13 201980
14 202480
15 201976
16 201573
17 201970
18 201865
19 201162
20 202361

About Eva Muñoz‐Couselo

Eva Muñoz‐Couselo is a scholar working on Oncology, Cancer Research, Molecular Biology, Epidemiology and Pulmonary and Respiratory Medicine, having authored 155 papers that have together received 4.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (71 papers), Melanoma and MAPK Pathways (30 papers), Cutaneous Melanoma Detection and Management (21 papers), Nonmelanoma Skin Cancer Studies (10 papers), Breast Cancer Treatment Studies (8 papers), Brain Metastases and Treatment (5 papers), Cancer Genomics and Diagnostics (5 papers) and Inflammatory Biomarkers in Disease Prognosis (4 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (620 citations), Cell Biology (262 citations), Molecular Biology (796 citations) and Immunology (157 citations). Eva Muñoz‐Couselo has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Javier Cortés, José Manuel Pérez-García, Carolina Ortiz, Peter E. Schmid, Vassiliki Karantza, Rebecca Alexandra Dent, Seock‐Ah Im, Esther Zamora, Mar Riveiro‐Barciela and Josep M. Tabernero. Their work appears in journals such as Annals of Oncology, Clinical & Translational Oncology, European Journal of Cancer, Clinical Cancer Research and Melanoma Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact